tldrdailynews.com logo

Gilead's Lenacapavir Dilemma: A HIV Breakthrough Hindered by Access Rules

1 min read
Source: Los Angeles Times
Gilead's Lenacapavir Dilemma: A HIV Breakthrough Hindered by Access Rules
Photo: Los Angeles Times
TL;DR

Lenacapavir could be a game-changer in HIV, but Gilead’s practice of not selling directly to Doctors Without Borders (MSF), limiting supply via the Global Fund to just 2 million doses over three years, and its licensing that excludes 26 middle-income countries has sparked criticism that profits trump public health. Gilead argues it is expanding access through generic licenses and deals with Global Fund and PEPFAR to deliver low- or no-profit supply, with a broader rollout planned in 2027 via generics in 120 countries, but concrete expansion remains uncertain.

Topics:healthbusiness#access-to-medicines#business#gilead#hiv#lenacapavir#msf
Share this article
  1. Commentary: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people  Los Angeles Times
  2. Open letter to Gilead: Prevention should not be a privilege  doctorswithoutborders.ca
  3. MSF wants to buy groundbreaking HIV prevention drug. Why won’t Gilead sell?  doctorswithoutborders.ca

Want the full story? Read the original reporting

Read on Los Angeles Times